NICE rejects Merck’s Keytruda kidney cancer combo, keeping pressure off BMS
Merck’s Keytruda may be pressuring Bristol-Myers Squibb’s Opdivo in kidney cancer in the U.S. But in England, cost watchdogs won’t be giving it the chance—at least for now. The National Institute for Health and Care Excellence (NICE) shot down the combination of Merck’s star and Pfizer’s Inlyta in previously untreated patients, citing uncertainty around the combo’s… Read More »